TRIESENCE Drug Patent Profile

✉ Email this page to a colleague

▶ Start for $1
Remove trial restrictions

When do Triesence patents expire, and when can generic versions of Triesence launch?

Triesence is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Triesence

A generic version of TRIESENCE was approved as triamcinolone acetonide by TARO on October 1^st, 1986.

Try a Trial

Summary for TRIESENCE

International Patents:	25
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	75
Clinical Trials:	10
Patent Applications:	2,768
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TRIESENCE
What excipients (inactive ingredients) are in TRIESENCE?	TRIESENCE excipients list
DailyMed Link:	TRIESENCE at DailyMed

Drug patent expirations by year for TRIESENCE

Recent Clinical Trials for TRIESENCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oxular Limited	Phase 2
Wake Forest University Health Sciences	Phase 4
Duke University	N/A

See all TRIESENCE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TRIESENCE

A01AC	Corticosteroids for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AB	Corticosteroids, moderately potent (group II)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XB	Corticosteroids, moderately potent, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for TRIESENCE

TRIESENCE is protected by three US patents.

Patents protecting TRIESENCE

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: VISUALIZATION DURING VITRECTOMY PROCEDURES

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Novartis	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for TRIESENCE

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TRIESENCE	triamcinolone acetonide	INJECTABLE;INTRAVITREAL	022048-001	Nov 29, 2007	See Plans and Pricing	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for TRIESENCE

See the table below for patents covering TRIESENCE around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Mexico	2010009974	SUSPENSIONES DE ACETONIDA DE TRIAMCINOLONA DE BAJA VISCOSIDAD, ALTAMENTE FLOCULADAS PARA INYECCION INTRAVITREA. (LOW VISCOSITY, HIGHLY FLOCCULATED TRIAMCINOLONE ACETONIDE SUSPENSIONS FOR INTRAVITREAL INJECTION.)	See Plans and Pricing
Japan	2011513492		See Plans and Pricing
Argentina	070824	SUSPENSIONES PARA INYECCION INTRAVITREA DE TRIAMCINOLONA ACETONIDO DE BAJA VISCOSIDAD, ALTAMENTE FLOCULADAS	See Plans and Pricing
Taiwan	200940071	Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection	See Plans and Pricing
European Patent Office	2262506	SUSPENSIONS D ACÉTONIDE DE TRIAMCINOLONE TRÈS FLOCULÉES ET DE FAIBLE VISCOSITÉ POUR INJECTION INTRAVITRÉENNE (LOW VISCOSITY, HIGHLY FLOCCULATED TRIAMCINOLONE ACETONIDE SUSPENSIONS FOR INTRAVITREAL INJECTION)	See Plans and Pricing
Uruguay	31699	SUSPENSIONES DE ACETONIDO DE TRIAMCINOLONA DE BAJA VISCOSIDAD Y ELEVADA FLOCULACION PARA INYECCION INTRAVITREA	See Plans and Pricing
World Intellectual Property Organization (WIPO)	2009114521		See Plans and Pricing
>Country	>Patent Number	>Title	>Estimated Expiration

Time limited offer for new users ▶ Get up to 3 months free